Reference: Planer et al. International Journal of Cardiology 2012 (in press) Prognosis of patients enrolled in acute myocardial infarction with ST segment elevation (STEMI) has improved markedly, particularly as a result of reperfusion therapy. Despite these improvements, patients with diabetes mellitus (DM) are a high risk group in the short and long term compared with<a href="https://solaci.org/en/2012/09/01/n-3956/" title="Read more" >...</a>
James SK, Storey RF, Khurmi N, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012. A sub-analysis of the PLATO study demonstrated similar superiority and the safety of ticagrelor in all patients, regardless of any previous history of stroke. Ticagrelor versus clopidogrel:<a href="https://solaci.org/en/2012/09/01/n-3984/" title="Read more" >...</a>
Reference: Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as<a href="https://solaci.org/en/2012/09/01/n-3949/" title="Read more" >...</a>
Platelet Inhibition in the PLATO study: insights from the ECG substudy. En el Estudio PLATO quedó evidenciado que el Ticagrelor disminuyó la mortalidad a 12 meses en comparación con el Clopidogrel en el tratamiento de pacientes post-angioplastía por un síndrome coronario agudo o por un cuadro estable (4,5 vs. 5,9%; P<0.001). Estos resultados fueron del<a href="https://solaci.org/en/2011/01/01/n-4026/" title="Read more" >...</a>